0
The impact of the first dose of the COVID-19 vaccines
The first national population-level study has shed light on the effect of the first dose of the COVID-19 vaccine. The…
Browsing: Clinical > Vaccines
0
Pfizer/BioNTech COVID-19 vaccine approved for use by UK regulator
Pfizer and BioNTech’s COVID-19 vaccine has been approved for use by the UK’s regulator, MHRA, making it the first COVID-19…
0
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
0
Moderna’s COVID-19 vaccine demonstrates 94.5% efficacy
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…
0
Pfizer and BioNTech’s COVID-19 vaccine 90% effective in Phase III trial
The first set of data from Pfizer (NY, USA) and BioNTech’s (Mainz, Germany) Phase III clinical trial for their COVID-19…
0
Accelerate your COVID-19 bioanalytical research while saving time and reducing cost
Wednesday 18 November 2020 11:00 [EST] 08:00 [PST] 16:00 [GMT] Alternative time zones REGISTER NOW The pharmaceutical industry is in…
0
What is the extent of SARS-CoV-2 immunity post-exposure?
The question of COVID-19 immunity is on everyone’s lips. It is crucial to understand how immunity develops post-exposure to the virus…
0
New antibody test for SARS-CoV-2
A new SARS-CoV-2 antibody test has been developed with improved accuracy and higher sample throughput at a lower cost in…
0
In Focus: studying the COVID-19 pandemic – a Special Focus Issue
Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
0
AstraZeneca COVID-19 vaccine trial resumed in the UK after safety evaluation
AstraZeneca and Oxford University (UK) have resumed the progress of their Phase III COVID-19 vaccine trial after investigating unexpected side effects in a patient enrolled in the trial in the UK.